Immunotherapy for gynaecological malignancies

George Coukos, Jose R. Conejo-Garcia, Richard B.S. Roden, T. C. Wu

Research output: Contribution to journalReview articlepeer-review

32 Scopus citations


Gynaecological malignancies, excluding breast cancer, cause ∼ 25,000 deaths yearly among women in the US. Therefore, novel approaches for the prevention or treatment of these diseases are urgently required. In the case of cervical cancer, human papillomavirus (HPV) xenoantigens are readily recognised by the immune system, and their targeting has shown great promise in preclinical models of therapeutic vaccination and in clinical studies of peventative vaccination. A growing body of evidence indicates that ovarian cancer is also immunogenic and can thus be targeted through immunotherapy. This review outlines the principles and problems of immunotherapy for cervical and ovarian cancer, including the authors' personal assessment.

Original languageEnglish (US)
Pages (from-to)1193-1210
Number of pages18
JournalExpert Opinion on Biological Therapy
Issue number9
StatePublished - Sep 2005


  • Cervical cancer
  • Cytokine
  • HPV
  • Immunotherapy
  • Lymphocyte
  • Ovarian cancer
  • Tumour-infiltrating
  • Vaccine development

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry


Dive into the research topics of 'Immunotherapy for gynaecological malignancies'. Together they form a unique fingerprint.

Cite this